A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)
Public ClinicalTrials.gov record NCT01503944. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Detection of Striatal Dopaminergic Degeneration and Neocortical Amyloid Pathology in Patients With Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease, and Healthy Elderly Volunteers
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the ability to identify individuals with dopaminergic degeneration in group of patients with a clinical diagnosis of either dementia with Lewy bodies (DLB) or idiopathic Parkinson's disease and to differentiate them from Alzheimer's disease (AD) and control subjects.
Study identification
- NCT ID
- NCT01503944
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 30 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 28, 2010
- Primary completion
- Jun 30, 2011
- Completion
- Jun 30, 2011
- Last update posted
- Aug 13, 2012
2010 – 2011
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Sun City | Arizona | — | — |
| Research Site | Philadelphia | Pennsylvania | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Alzheimer's Disease trials
Other public records listing Alzheimer's Disease. Sorted by last update posted; newest first. Not a recommendation.
- NCT07780383: A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration Not yet recruiting
- NCT07775625: Central Auditory Processing Modulation Underlying Anxiety Reduction Using Clinically Designed Improvisatory Music Recruiting
- NCT06976203: A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) Recruiting
- NCT07688213: A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease Recruiting
- NCT07721467: Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin Not yet recruiting
- NCT00869817: Dominantly Inherited Alzheimer Network (DIAN) Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01503944, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 13, 2012 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01503944 live on ClinicalTrials.gov.